Atlas Brown Inc. Purchases 167 Shares of CVS Health Co. (NYSE:CVS)

Atlas Brown Inc. raised its stake in CVS Health Co. (NYSE:CVSGet Rating) by 1.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,833 shares of the pharmacy operator’s stock after acquiring an additional 167 shares during the period. Atlas Brown Inc.’s holdings in CVS Health were worth $911,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CVS. Revolve Wealth Partners LLC lifted its position in shares of CVS Health by 2.8% during the 1st quarter. Revolve Wealth Partners LLC now owns 4,328 shares of the pharmacy operator’s stock worth $438,000 after buying an additional 119 shares during the last quarter. Acropolis Investment Management LLC increased its stake in shares of CVS Health by 77.1% in the first quarter. Acropolis Investment Management LLC now owns 3,018 shares of the pharmacy operator’s stock valued at $305,000 after buying an additional 1,314 shares during the period. Glassy Mountain Advisors Inc. increased its stake in shares of CVS Health by 1.1% in the first quarter. Glassy Mountain Advisors Inc. now owns 72,680 shares of the pharmacy operator’s stock valued at $7,356,000 after buying an additional 825 shares during the period. DeDora Capital Inc. acquired a new stake in shares of CVS Health in the first quarter valued at about $68,000. Finally, Equitable Trust Co. increased its stake in shares of CVS Health by 2.7% in the first quarter. Equitable Trust Co. now owns 7,114 shares of the pharmacy operator’s stock valued at $720,000 after buying an additional 186 shares during the period. 77.64% of the stock is owned by institutional investors and hedge funds.

CVS Health Price Performance

CVS stock traded down $2.22 during mid-day trading on Friday, hitting $97.61. 257,546 shares of the stock were exchanged, compared to its average volume of 4,398,985. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.91 and a quick ratio of 0.65. The business has a fifty day moving average price of $100.14 and a 200 day moving average price of $99.28. CVS Health Co. has a 12 month low of $81.78 and a 12 month high of $111.25. The stock has a market capitalization of $128.15 billion, a price-to-earnings ratio of 15.91, a PEG ratio of 1.52 and a beta of 0.73.

CVS Health (NYSE:CVSGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The pharmacy operator reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.24. CVS Health had a return on equity of 15.19% and a net margin of 2.65%. The firm had revenue of $80.64 billion during the quarter, compared to analyst estimates of $76.38 billion. During the same quarter in the previous year, the company posted $2.42 earnings per share. The company’s revenue was up 11.0% compared to the same quarter last year. On average, sell-side analysts anticipate that CVS Health Co. will post 8.53 EPS for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Stockholders of record on Friday, October 21st will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.25%. The ex-dividend date of this dividend is Thursday, October 20th. CVS Health’s dividend payout ratio (DPR) is presently 35.77%.

Insider Activity

In other CVS Health news, EVP Alan Lotvin sold 22,541 shares of the company’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $104.00, for a total transaction of $2,344,264.00. Following the completion of the transaction, the executive vice president now owns 109,183 shares of the company’s stock, valued at approximately $11,355,032. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other CVS Health news, EVP Alan Lotvin sold 22,541 shares of the company’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $104.00, for a total transaction of $2,344,264.00. Following the completion of the transaction, the executive vice president now owns 109,183 shares of the company’s stock, valued at approximately $11,355,032. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Thomas M. Moriarty sold 138,654 shares of the company’s stock in a transaction that occurred on Tuesday, June 28th. The stock was sold at an average price of $95.00, for a total value of $13,172,130.00. Following the transaction, the executive vice president now owns 626,273 shares in the company, valued at approximately $59,495,935. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Credit Suisse Group raised their target price on CVS Health from $113.00 to $117.00 and gave the stock an “outperform” rating in a research note on Monday, August 8th. UBS Group raised their target price on CVS Health from $118.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, August 4th. Deutsche Bank Aktiengesellschaft raised their target price on CVS Health from $113.00 to $120.00 in a research note on Thursday, August 4th. Sanford C. Bernstein cut CVS Health from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $122.00 to $112.00 in a research note on Thursday, May 26th. Finally, Mizuho lifted their price target on CVS Health from $115.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, August 15th. Four analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average target price of $117.59.

About CVS Health

(Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

See Also

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSGet Rating).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.